Proud to share our new @Nature study: We developed the 1st NNMT inhibitor that reprograms cancer-associated fibroblasts, boosting immune response & stopping tumor growth in ovarian cancer models, especially when paired with immunotherapy. @OvCa_UChicagonature.com/articles/s4158…
Is there a difference in outcomes for patients receiving morning or evening chemoimmunotherapy infusion ? #ASCO25 we have the first randomized trial and its positive!
Several retrospective studies showed that morning immunotherapy infusions are associated with longer survival. However, there was always the question of systematic bias selecting for healthier patients in morning infusions, when frailer patients may not be able to come to receive morning infusions. This could potentially explain retrospective results, that may seem too good to be true…
Now we have a randomized clinical trial coming from Dr Zhang and colleagues showing a hazard ratio for Overall Survival of … 0.45 ! Lung cancer, chemo-immunotherapy first-line
Looking forward to dig further into the data, and these findings for sure have to be replicated (we are working on that 🇨🇭 @SAKK_ch)
But impressive efforts and results, congrats to the authors.👏 @Alfdoc2
Check out our 2024 year in review videos for a meeting-by-meeting summary of highlights across GU malignancies at uromigos.org in collaboration with @ToplineBio
We are excited to partner with @ToplineBio Topline Bio for a new era of digital education and storytelling to serve both the healthcare professionals treating #kidneycancer and the patients and families impacted.
Read more: kidneycancer.org/kca-toplinebio/
@Uromigos : Further efforts in advanced bladder cancer will focus on how to optimize the amount of therapy for a given patient so as not to overtreat patients and expose them to excess toxicity without additional benefit.
@Uromigos : Further efforts in advanced bladder cancer will focus on how to optimize the amount of therapy for a given patient so as not to overtreat patients and expose them to excess toxicity without additional benefit.
Dr. Powles of the @Uromigos sinks his teeth into ctDNA as an emerging, powerful tool to monitor prostate patients on therapy and how it may add to existing prognostic models…
KIM-1 is a soluble protein with prognostic and predictive potential in resected RCC. For more from the @Uromigos on the data from IMmotion 010, click the link below…
shorturl.at/uLNXN
Follow Topline Bio for more from @brian_rini👍👍 Chemotherapy plus nivolumab has benefit in advanced bladder cancer, especially in the biologically-distinct subset of patients with lymph node only disease, just ask @Uromigos
Chromophobe RCC is a rare subtype of kidney cancer. Clinical outcomes from a large institution-based cohort are presented supporting IO-based combination therapy. @brian_rini shares his perspective…
@Uromigos focus on CDK 4/6 inhibition. CDK 4/6 did not produce benefit in mCRPC in a large phase 3 trial and the role of CDK inhibition in prostate cancer remains uncertain.
@Uromigos discuss Enfortumab vedotin (EV), an active agent in advanced bladder cancer and its efficacy/toxicity related to drug exposure. Early recognition and management of toxicity is critical…
The emergence of more active bladder cancer systemic therapy has led to more patients with initial advanced disease who could be considered for consolidative cystectomy. @Uromigos debate the timing and role of this maneuver…
@Uromigos discussing the combination of Abiraterone/Cabazitaxel and its modest clinical benefit in taxane-refractory mCRPC… but is it likely to affect clinical practice?
Enjoy the full clip here : shorturl.at/dr4Uz
@Uromigos discuss recent data regarding biomarkers of response in metastatic clear cell carcinoma. Some advances have been made yet more work is required to impact patient care… #gucancer#kidneycancer#ASCO24
The exciting advancements of targeted therapies in gynecologic cancer brings hope to patients. 2024 has been an exciting year for the integration of targeted therapies in GYN oncology, bringing hope to patients and providers alike. #cervicalcancer#endometrialcancer
362 Followers 503 FollowingGU Medical Oncologist @Mskcancercenter @MSK_DeptofMed via @ColumbiaCancer @WeillCornell @Jacobs_med_UB and @BarnardCollege Alum. Tweets/opinions my own
2K Followers 404 FollowingProfessor of Medicine, Grover C Bagby Endowed Chair in Prostate Cancer Research, Genitourinary Oncology Program Director, Knight Cancer Institute OHSU
173 Followers 599 FollowingSignifyMD makes expert medical insights accessible and actionable for today’s oncologists and HCPs.
#Oncology #Cancer #MedTwitter
10K Followers 1K FollowingThe KCA is a global community dedicated to serving and empowering patients and caregivers, and leading change through advocacy, research, and education.
8K Followers 483 FollowingThe Uromigos strives to provide balanced, scientific content related to care of patients with GU malignancies. Click the link below to listen to our podcasts.
2K Followers 1K FollowingGU oncologist at Cleveland Clinic. Views/Tweets/RTs are my own & not medical advice. Author of Cancer in Halachah: https://t.co/pyUb3pPVBs
2K Followers 2K FollowingGenitourinary Oncology, Associate Professor, Vanderbilt University
Vice President, MRD Research and Clinical Strategy, Tempus AI
842 Followers 52 FollowingIgniting a systemic immune response to cancer. Our mission is to transform cancer treatment by pioneering novel oncolytic immunotherapies.
2K Followers 1K FollowingGU Medical oncologist, clinical trials and drug development, wife, mother, runner, animal lover. RCC, Bladder, and Prostate Cancer. Views are my own.
41 Followers 27 FollowingCataloging vintage, quirky, gay, tech, gaming and rare advertisements from famous and not so famous magazines. https://t.co/OnA66mru95
2K Followers 404 FollowingProfessor of Medicine, Grover C Bagby Endowed Chair in Prostate Cancer Research, Genitourinary Oncology Program Director, Knight Cancer Institute OHSU
362 Followers 503 FollowingGU Medical Oncologist @Mskcancercenter @MSK_DeptofMed via @ColumbiaCancer @WeillCornell @Jacobs_med_UB and @BarnardCollege Alum. Tweets/opinions my own
17K Followers 219 FollowingSVP Oncology Global Development @Amgen, Physician-Scientist, Medical Oncologist, immune and molecular target-believer, Tweets my own
10K Followers 1K FollowingThe KCA is a global community dedicated to serving and empowering patients and caregivers, and leading change through advocacy, research, and education.
4K Followers 2K FollowingOfficial twitter account of Team Ovary, the ovarian cancer service at Memorial Sloan Kettering Cancer Center, views are our own
2K Followers 319 FollowingGynecologic Oncologist at Policlinico Gemelli IRCCS, Rome, @ENYGO_official Past President, ENYGO Executive Group and @IJGConline Editorial Board Member
4K Followers 2K FollowingHead of GynOnc, Norwegian Radiumhospital @Oslounivsykehus | Ass. Prof. @UniOslo_MED | @ESGO_society President Elect | @OncoAlert
3K Followers 189 FollowingThe European Network of Young Gynae Oncologists (ENYGO) is a network for juniors and trainees in Gynaecological Oncology and related subspecialties.
82K Followers 1K FollowingThe European Society for Medical Oncology (ESMO) is a reference organisation for cancer education and information, supporting the oncology community’s work.
2K Followers 761 FollowingAssociate Professor, Medical Director O.C. Gynecologic Cancer Program, City of Hope Orange County (views reflected on Twitter are my own)
2K Followers 655 FollowingBreast oncologist @UCSF | Interested in breast cancer clinical/translational research, med ed | Author of Huppert’s Notes | Tweets my own
4K Followers 1K FollowingBreast & gyn med onc @valleyhealthnj. Opinions my own. Host of INTERLUDE podcast. 📗 BEYOND THE PINK (2026). Patient education on Instagram.
380 Followers 47 FollowingConference focused on theranostics. 2026 conference will be held in Los Angeles on March 26-27. Co-sponsored by UCLA/UCSF/PCF.
2K Followers 1K FollowingGU oncologist at Cleveland Clinic. Views/Tweets/RTs are my own & not medical advice. Author of Cancer in Halachah: https://t.co/pyUb3pPVBs
17K Followers 799 FollowingStay Up To Date with our Newsletter: https://t.co/BQxZ2gkon8 Delivering top-quality multimedia to oncologists, hematologists, and cancer pros!
1K Followers 1K FollowingAssistant Professor of Gynecologic Oncology @PennMedicine @PennCancer | Physician-Scientist | 🇪🇺🇬🇷➡️🇺🇸 | Opinions expressed are my own.